Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes. I'm having issue with level 2 and live quotes.
I have been following TPT for the past three years, and it is widely known that this company is a scam. However, there is no reason why we can't make money off of it. In my humble opinion, a unknown group is accumulating this stock, and it may be getting ready to push the price up to 0.3-0.7 cents in the next couple of weeks.
I think we will see $.03 before end of day. Somebody is buying this stock quietly(just before closing) and trying not to rise a price too much. If you want to get in do it right now before price go parabolic.
Very heathy trading. Expecting this to be much higher next week.
Ask at @ 0.02 LOL
Yesssss @ 0.0195
It’s on the website. 7 days a week from 10am-5pm.
Website is LIVE
http://thequiklab.com
Frank Benedetto
"App and website are not up because shareholders will inundate it just like they have Thomas Sci..we are opening tom and have special guests coming."
This is from Frank in FB
“ Let me chime in on this..
The Miami delay is unfortunate. When we realized that this would be the norm we pivoted and acquired Epic to resolve this problem going forward. We still have to wait out this CLIA issue on this first lab..I am confident that we will be up and running in the coming days. We are as unhappy as you are with this delay. “
So is this good or bad ?
WOW we are green, it’s a miracle!!’n
$OPK COVID-19 Tests Update
3.22.20: ACLA members, including ARUP, BioReference Laboratories ($OPK), LabCorp, Mayo Clinic Laboratories, Quest Diagnostics, and Sonic Healthcare have reported out approximately 183,000 tests to date, including 54,000 completed tests for March 21.
https://www.acla.com/covid-19/
$OPK(BioReference Laboratory) Drive-Through Testing to Expand
https://www.amny.com/health/drive-through-testing-to-expand-in-brooklyn-with-appointments/
Open at 2.85 on Frankfurt stock market !!!
I think with all the bad news about corona virus , INO will get lots of attention !!! And that means lots of money ??
Hahaha BURN shorts.....
What’s going on here?
Who is buying all this shares ?
Second run is starting ??
In at $.28, love this actin today. Will go much higher next week.
You should sell this pump and dump and buy JASN
Morning gap was filled. New daily high is coming .
I like days like this.
Now is 80 mil !
56 mil on the bid 0.006 L2
It’s a time for the price to go up !!!
BTCS 9K
Next week will be huge !!!
This is just so f***** up, they will never stop selling a shares....
There is the huge bid for over 4 mil. shares, maybe it's a good sign.
This stock is such a joke, never ending.
https://give.umn.edu/stories/clinical-trial-triumph
LOS ANGELES, Feb. 10, 2016 /PRNewswire/ -- Oxis International Inc. (OTC/QB: OXIS) announced today that the company's blood cancer drug, OXS-1550, was described as a "clinical trial triumph" after one of the first patients treated with the drug went into complete cancer remission.
An article on the University of Minnesota's website highlighted one patient whose aggressive and deadly form of cancer went into complete remission after she was treated with OXS-1550. The article described the history of the drug, which was developed by Dr. Daniel Vallera, a research scientist at the University of Minnesota Masonic Cancer Center.
The full text of the article is available here: https://give.umn.edu/stories/clinical-trial-triumph.
Vallera, a scholar and professor in the department of therapeutic radiology, has been studying cancer for more than 30 years. He said the new cancer treatment, which he originally named DT2219, is an injected biologic agent designed to identify cancer cells and kill them, while leaving healthy cells alone.
He has said OXS-1550 is an important alternative to chemotherapy, which kills both cancerous and healthy cells and creates toxicity problems for some patients.
Oxis International holds the worldwide commercial rights for the drug, which it acquired in 2015 and renamed OXS-1550. The Food and Drug Administration has authorized a Phase I/Phase II clinical trial.
One of the first patients to receive the drug was Cynthia Cattell, who said other treatments for her aggressive B-cell lymphoma had failed. Cattell received four infusions of the drug over an eight-day span in the Phase 1 clinical trial.
One month later, a doctor overseeing the clinical trial found a 75 percent reduction in the size of Cattell's tumor, the article said.
Cattell, a University of Minnesota physics professor, received a second round of treatments, which wiped out the tumor. She has been in complete remission for more than 18 months.
After the successful treatment, Cattell was introduced to Dr. Vallera.
Wow this really sucks ...
I think that everybody are speechless because oxis is not down , lol.
Can somebody explain the new 8-k, thanks.Good or bad!
Who is buying? Volume is over 10000
Now sold 100 shares for $6